Drugs / TQB3720
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04853498 | Jun 2021 → Apr 2024 | prostate carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3720 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04853498 ↗ |
| Route | Oral | “TQB3720 tablets administered orally, once daily in 28-day cycle.” NCT04853498 ↗ |